Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro

Marina Muzza, Daniela Cordella, Johny Bombled, Brigitte Bressac De Paillerets, Fabiana Guizzardi, Zelia Francis, Paolo Beck-Peccoz, Martin Schlumberger, Luca Persani, Laura Fugazzola

Research output: Contribution to journalArticle

Abstract

Context: Most germline-activating mutations of the RET proto-oncogene associated with inherited medullary thyroid cancer (MTC) are localized in exons 10, 11 and 13-15. Four novel RET variants, located in the extracellular domain (p.A510V, p.E511K and p.C531R) coded by exon 8 and in the intracellular juxtamembrane region (p.K666N) coded by exon 11, were identified on the leukocyte DNA from apparently sporadic cases. Methods: Plasmids carrying Ret9-wild-type (Ret9-WT), Ret9-C634R and all Ret9 variants were transfected, and the phosphorylation levels of RET and ERK were evaluated by western blot analyses. The transforming potentials were assessed by the focus formation assay. Results: The p.A510V, p.E511K and p.C531R variants were found to generate RET and ERK phosphorylation levels and to have a transforming activity higher than that of Ret9-WT variant, but lower than that of Ret9-C634R variant. Differently, the p.K666N variant, located immediately downstream of the transmembrane domain, and involving a conserved residue, displayed high kinase and transforming activities. Computational analysis predicted non-conservative alterations in the mutant proteins consistent with putative modifications of the receptor conformation. Conclusions: The molecular analyses revealed an oncogenic potential for all the novel germline RET variants. Therefore, the prevalence of exon 8 genomic variations with an oncogenic potential may be higher than previously thought, and the analysis of this exon should be considered after the exclusion of mutations in the classical hotspots. In addition, on the basis of these functional data, it is advisable to extend the genetic screening to all the first-degree relatives of the MTC patients, and to perform a strict follow-up of familial carriers.

Original languageEnglish
Pages (from-to)771-777
Number of pages7
JournalEuropean Journal of Endocrinology
Volume162
Issue number4
DOIs
Publication statusPublished - Apr 1 2010

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro'. Together they form a unique fingerprint.

  • Cite this

    Muzza, M., Cordella, D., Bombled, J., Paillerets, B. B. D., Guizzardi, F., Francis, Z., Beck-Peccoz, P., Schlumberger, M., Persani, L., & Fugazzola, L. (2010). Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro. European Journal of Endocrinology, 162(4), 771-777. https://doi.org/10.1530/EJE-09-0929